Pre-treatment with Hesperidin at 25 and 50 μM and DRB at 0.25 and 0.5 μM for 24 h increased ADAM10 gene expression and decreased BACE1 gene expression, both of which are associated with AD markers, compared to the 20 μM Aβ1-42 treatment group (p < 0.05). This evidence concerns the gene ADAM10 and Alzheimer disease.